Esophageal Cancer Market Report 2025

The esophageal cancer market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increased number of cancers, improvement in healthcare infrastructure, rise in alcohol consumption, growth in demand for preventive healthcare solutions, increase in prevalence of esophageal adenocarcinoma.

The esophageal cancer market size is expected to see strong growth in the next few years. It will grow to $2.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising prevalence of esophageal cancer, increasing public understanding of healthcare, improvements in healthcare infrastructure, chronic consumption of smoking and alcohol, increasing prevalence of esophageal adenocarcinoma. Major trends in the forecast period include technological advancements in treatment options, increased investment in research and development, increasing utilization of precision medicine, development of targeted therapies, increased participation in clinical trials and collaborations between academia, pharmaceutical companies, and healthcare institutions.

The rising incidence of esophageal cancer is expected to drive growth in the esophageal cancer market. Esophageal cancer is a malignancy that affects the esophagus, the tube connecting the throat to the stomach. As more cases are diagnosed, there will be an increased demand for diagnostic procedures such as endoscopy, imaging tests, and biopsies to detect and confirm the disease. For example, the American Cancer Society, a US-based professional organization, reported that in 2023, there were 16,120 new deaths from esophageal cancer, with projections indicating this number will rise to 16,130 in 2024. Therefore, the increase in esophageal cancer cases is anticipated to propel the growth of the esophageal cancer market.

Increased consumption of alcohol is also anticipated to fuel the growth of the esophageal cancer market. Alcohol consumption involves ingesting beverages containing ethanol, which metabolizes into acetaldehyde, a known carcinogen that can damage DNA in esophageal cells. Chronic alcohol consumption can lead to inflammation and irritation in the esophageal lining, creating a conducive environment for cancer development. Notably, in November 2023, data from the Substance Abuse and Mental Health Services Administration (SAMHSA) revealed a rise in alcohol consumption among the 133.1 million current alcohol users aged 12 or older in the United States in 2021. Of these, 25.8 percent reported binge drinking in the past month, and 6.3 percent reported heavy alcohol use during the same period. Moreover, 14.4 million individuals aged 12 or older experienced an alcohol use disorder in the past year, constituting 5.3 percent of people in this age group. Consequently, high alcohol consumption is expected to contribute to the growth of the esophageal cancer market.

The approval of new drugs stands out as a significant trend gaining traction in the esophageal cancer market. Major companies within the esophageal cancer market are directing their efforts towards securing approvals for new drugs, a strategy aimed at enhancing their market position and gaining a competitive edge. An illustrative example is Bristol Myers Squibb, a US-based pharmaceutical company, which obtained approval from the U.S. Food and Drug Administration (FDA) in May 2022 for two of its products such as Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab). These products, primarily designed for individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), received authorization based on favorable outcomes observed in Phase 3 clinical trials, demonstrating improved overall survival rates among treated patients.

A focus on precision medicine is also evident among major companies operating in the esophageal cancer market, as reflected in product launches. Precision medicine represents an innovative approach to medical treatment that tailors interventions based on individual patients' unique genetic, environmental, and lifestyle characteristics. Previse, a US-based biotechnology company, launched Esopredict in March 2023 - a precision medicine solution empowering gastroenterologists to tailor approaches effectively for managing the risk of future cancer diagnoses. Esopredict utilizes The Esoscore derived from Barrett’s esophagus cells to offer timely and accurate 5-year risk predictions for esophageal cancer. This groundbreaking product addresses an essential medical need by aiding healthcare providers in identifying patients at risk of progressing to high-grade dysplasia or esophageal cancer, thereby revolutionizing treatment approaches and significantly impacting the esophageal cancer market.

In January 2023, ProPhase Labs, Inc., a US-based next-generation biotech, genomics, and diagnostics company, acquired the rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test from Stella Diagnostics, Inc. This strategic move positions ProPhase Labs to facilitate healthcare providers in promptly initiating life-saving early treatment measures, such as ablation procedures to eliminate precancerous cells. Stella Diagnostics, Inc., a US-based molecular diagnostics organization, focuses on enhancing patient management strategies.

Major companies operating in the esophageal cancer market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Servier Pharmaceuticals, Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Ipsen SA, Dr. Reddy's Laboratories Ltd., Seagen Inc., Exelixis Inc., BeiGene Ltd., Clovis Oncology Inc., Aslan Pharmaceuticals Ltd.

North America was the largest region in the esophageal cancer market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esophageal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the esophageal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Esophageal cancer is a form of cancer originating in the cells that line the esophagus, the muscular tube responsible for transporting food and liquids from the neck to the stomach. This malignancy occurs when abnormal cells within the esophagus undergo uncontrolled growth, leading to the development of cancer.

The primary classifications of esophageal cancer include esophageal squamous-cell carcinoma, esophageal adenocarcinoma, and other subtypes. Esophageal squamous-cell carcinoma specifically emerges from the squamous cells lining the esophagus. Treatment options encompass chemotherapy, targeted therapy, and various other approaches, which can be administered orally, parenterally, and through alternative methods. The distribution of treatment products occurs through channels such as hospital pharmacies, online pharmacies, and retail pharmacies, serving institutions such as hospitals, homecare services, specialty centers, and other healthcare facilities.

The esophageal cancer research report is one of a series of new reports that provides esophageal cancer market statistics, including the esophageal cancer industry's global market size, regional shares, competitors with a esophageal cancer market share, detailed esophageal cancer market segments, market trends and opportunities, and any further data you may need to thrive in the esophageal cancer industry. This esophageal cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The esophageal cancer market consists of revenues earned by entities by providing esophageal cancer treatment services such as esophagectomy, palliative care, and brachytherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The esophageal cancer market consists of sales of fluorouracil, capecitabine, cisplatin, epirubicin, and docetaxel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.